Corrected Claims:

In response to the Notice of Non-Compliant Amendment, this listing of claims will replace the prior version submitted with the 14 December 2007 Amendment and Response to Restriction Requirement.

Listing of Claims:

Claim 1. (Currently amended) A method for diagnosing a genetic susceptibility for an inflammatory bowel disease in a subject, such method comprising:

a. obtaining a biological sample containing nucleic acid from said subject, and

b. analyzing said nucleic acid to detect the presence or absence of a single nucleotide polymorphism in a CSFIR gene ~~selected from the group consisting of FLJ21425 and CSF1R~~, wherein said single nucleotide polymorphism is associated with a genetic predisposition for inflammatory bowel disease.

Claim 2. (original) The method of claim 1, wherein at least one single nucleotide polymorphism is located at 2033 base pairs from the 3′ end of the eleventh intron of the CSF1R gene.

Claim 3. (original) The method of claim 1, wherein said nucleic acid is DNA, RNA, cDNA or mRNA.

Claim 4. (original) The method of claim 1, wherein said analysis is accomplished by sequencing, mini sequencing, hybridization, restriction fraction analysis, oligonucleotide ligation assay or allele specific PCR.

Claim 5. (currently amended) The method of claim 4, wherein said analysis is accomplished using primers selected from the group consisting of ~~SEQ. ID. No. 1, SEQ. ID. No. 2,~~ SEQ. ID. No. 3, and SEQ. ID. No. 4.

Claim 6. (original) A method as in Claim 1, wherein said inflammatory bowel disease is Crohn's disease.

Claim 7. (Currently amended) A method of treatment or prophylaxis in a subject, said method comprising:

a. obtaining a sample of biological material containing nucleic acid from a subject;

b. analyzing said nucleic acid to detect the presence or absence of a least one single nucleotide polymorphism of a CSFIR gene ~~selected from the group consisting of FLJ21425 and CSFIR~~ associated with a genetic predisposition for inflammatory bowel disease; and

c. treating the subject for inflammatory bowel disease.

Claim 8. (original) The method of claim 7, wherein at least one single nucleotide polymorphism is located at 2033 base pairs from the 3′ end of the eleventh intron of the CSF1R gene.

Claim 9. (original) The method of claim 7, wherein said nucleic acid is DNA, RNA, cDNA or mRNA.

Claim 10. (original) The method of claim 7, wherein said analysis is accomplished by sequencing, mini sequencing, hybridization, restriction fraction analysis, oligonucleotide ligation assay or allele specific PCR.

Claim 11. (Currently amended) The method of claim 10, wherein said analysis is accomplished using primers selected from the group consisting of ~~SEQ. ID. No. 1, SEQ. ID. No. 2,~~ SEQ. ID. No. 3, and SEQ. ID. No. 4.

Claim 12. (original) A method as in Claim 7, wherein said inflammatory bowel disease is Crohn's disease.

Claim 13. (original) A method as in Claim 7, wherein said treatment comprises administering to the subject one or more drugs known to affect expression of the CSF1R gene.

Claim 14. (original) A method as in claim 13, wherein said drugs are selected from the group comprising corticosteroids, retinoic acids, interleukin 10, vitamin D3, and mifepristone.